Alphyn Biologics, Inc.
- | Biotech or pharma, animal health
Alphyn is using its AB-101 drug platform to develop safer, more effective therapeutics, initially for the $118 Billion Atopic Dermatitis (AD) market. After only 3½ years Alphyn’s 1st drug candidate, topical AB-101a, completed two Phase 2a clinical trials
Address
AnnapolisMD
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}